Mounia Chaoui joined Ventech in 2001 and is a General Partner, driving investments in Life Sciences. She brings to Ventech her investor experience in Life Sciences and her expertise in building international syndications.
Mounia has sat or is still sitting on the boards of BioVex (acquired by Amgen for $1B), Cellerix (now EBR : TIGENIX), Eyegate, Inserm Transfert Initiative, Tigenix and Xytis, and is represented by an independent board member on Scynexis board.
Mounia started her career as analyst in the Life Sciences team at Atlas Venture, a venture capital firm. Then she conducted strategic audits covering both organisational and technical aspects at Altran. She also performed due diligence procedures on behalf of financial investors and was involved in fund-raising for start-ups.
Mounia Chaoui graduated as an engineer from École Centrale de Paris and holds a Ph.D. in Molecular Biophysics.